Amicus Therapeutics (FOLD) : Traders are bullish on Amicus Therapeutics (FOLD) as it has outperformed the S&P 500 by a wide margin of 13.27% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 12.07%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 12% in the last 1 week, and is up 17.07% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 11.71% and the 50-Day Moving Average is 7.12%. Amicus Therapeutics, Inc. has dropped 10.04% during the last 3-month period . Year-to-Date the stock performance stands at -30.72%.
Amicus Therapeutics (NASDAQ:FOLD): On Fridays trading session , Opening price of the stock was $6.78 with an intraday high of $6.78. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $6.45. However, the stock managed to close at $6.72, a loss of 1.18% for the day. On the previous day, the stock had closed at $6.8. The total traded volume of the day was 2,127,955 shares.
Also, Bank of America initiates coverage on Amicus Therapeutics (NASDAQ:FOLD) In a research note issued to the investors, the brokerage major announces price-target of $10 per share.The shares have been rated Buy. The rating by the firm was issued on May 18, 2016.
Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (SDs). The Companys lead product candidate is the pharmacological chaperone migalastat HCl (Galafold), a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Companys development programs also include ERTs for LSDs, including Fabry disease, Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Companys programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as ERT products for Fabry disease, Pompe disease and MPS I.